Low-dose IL-2 reduces IL-21(+) T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes

Despite early clinical successes, the mechanisms of action of low-dose interleukin-2 (LD-IL-2) immunotherapy remain only partly understood. Here we examine the effects of interval administration of low-dose recombinant IL-2 (iLD-IL-2) in type 1 diabetes using high-resolution single-cell multiomics a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jia-Yuan, Hamey, Fiona, Trzupek, Dominik, Mickunas, Marius, Lee, Mercede, Godfrey, Leila, Yang, Jennie H. M., Pekalski, Marcin L., Kennet, Jane, Waldron-Lynch, Frank, Evans, Mark L., Tree, Timothy I. M., Wicker, Linda S., Todd, John A., Ferreira, Ricardo C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705541/
https://www.ncbi.nlm.nih.gov/pubmed/36443294
http://dx.doi.org/10.1038/s41467-022-34162-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705541/
https://www.ncbi.nlm.nih.gov/pubmed/36443294
http://dx.doi.org/10.1038/s41467-022-34162-3

Ejemplares similares